This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
MFA Financial Gears Up to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
MFA's third-quarter 2024 results are likely to reflect the benefits of loan demand. Declines in earnings assets are expected to have offset growth.
NexPoint Real Estate Finance to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
NREF's third-quarter 2024 results are likely to gain from declining mortgage rates, although a decrease in NII poses a challenge.
Key Factors Influencing Two Harbors Investment's Q3 Earnings
by Zacks Equity Research
TWO's third-quarter 2024 results are expected to benefit from lower mortgage rates, though the negative NII remains a challenge.
Is the Options Market Predicting a Spike in American Healthcare REIT, Inc. (AHR) Stock?
by Zacks Equity Research
Investors need to pay close attention to American Healthcare REIT, Inc. (AHR) stock based on the movements in the options market lately.
Key Factors to Know Ahead of ARMOUR Residential REIT's Q3 Earnings
by Zacks Equity Research
ARR's third-quarter 2024 results are likely to reflect the impacts of high funding costs. High prepayment speed is expected to have supported.
What's in the Cards for Healthpeak Properties This Earnings Season?
by Zacks Equity Research
DOC's Q3 earnings are likely to have benefited from rising healthcare spending and the aging population. However, higher interest expenses may have hurt it.
Annaly Scheduled to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
NLY's third-quarter 2024 results are likely to reflect the impacts of increased funding costs. High prepayment speed is likely to have aided.
Best Momentum Stocks to Buy for September 27th
by Zacks Equity Research
MHO, RACE and AHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 27, 2024.
American Healthcare REIT (AHR) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
American Healthcare REIT (AHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for September 23rd
by Zacks Equity Research
AU, AHR and HWM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 23, 2024.
New Strong Buy Stocks for September 23rd
by Zacks Equity Research
OPRA, SBSI, AU, AHR and LYTS have been added to the Zacks Rank #1 (Strong Buy) List on September 23, 2024.
Implied Volatility Surging for American Healthcare (AHR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to American Healthcare (AHR) stock based on the movements in the options market lately.
Implied Volatility Surging for American Healthcare (AHR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to American Healthcare (AHR) stock based on the movements in the options market lately.
Is a Surprise Coming for American Healthcare (AHR) This Earnings Season?
by Zacks Equity Research
American Healthcare (AHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.